PFM Health Sciences and Farallon Capital Management led a $175m Series B round in Metagenomi, a genetic medicines company, with participation from Eventide Asset Management, Deep Track Capital, Frazier Life Sciences, Pura Vida Investments, Irving Investors, Millennium Management, Surveyor Capital, Marshall Wace, Novo, Bristol Myers Squibb, Moderna, RA Capital Management, Leaps by Bayer, and Humboldt Fund. "Metagenomi’s method of discovering novel and versatile gene editing systems from nature is scientifically compelling and differentiated. We are thrilled to be able to support Metagenomi as they advance their gene editing programs towards the clinic. Their gene editing systems hold the potential to have major benefits for patients," Santhosh Palani, PFM Health Sciences Partner.